Investor Dashboard

On 10 March 2023 Neuren’s partner Acadia Pharmaceuticals received marketing approval from the U.S. Food and Drug Administration (FDA) for DAYBUE™ (trofinetide) to treat Rett syndrome in adults and pediatric patients 2 years of age and older in the United States.

Latest Announcements

Read More >>

Annual & Interim Reports

Read More >>

Annual Reports

Presentations

Factsheet

Subscribe to our Email Alerts

Sign up to our email alerts to get the latest news and updates delivered directly in your inbox.